STARPHARMA HOLDINGS LIMITED
ASX:SPLPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 91.9% of what they think they own, once every option and right converts.
Share count grew 14% in 24 months; 1 cash raise in 24 months; options/rights overhang 9% of shares
STARPHARMA HOLDINGS LIMITED's ordinary share count grew 14.3% between August 2024 and August 2026, to 477M shares. In the past 24 months, the company raised capital once via an Entitlement Offer in July 2026, bringing in A$32.0M, the total amount raised in this period. Options and rights on issue could convert into 42M new shares, representing 8.8% of the current share count, though no expiry date is on record. None of these options are currently in the money. As of the June 2026 quarter, the company reported A$40.4M in available cash, which provided cover for 12.4 quarters based on recent spending rates. No proposed securities issues are currently pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 10 Aug 2026 | 2A · quoted issue | SPL : ORDINARY FULLY PAID | 477.1M | Appendix 2A |
| 6 Apr 2026 | 2A · quoted issue | SPL : ORDINARY FULLY PAID | 420.9M | Appendix 2A |
| 7 Jan 2026 | 3H · cancellation | SPL : ORDINARY FULLY PAID | 418.2M | Appendix 3H |
| 7 Jan 2026 | 2A · quoted issue | SPL : ORDINARY FULLY PAID | 419.9M | Appendix 2A |
| 17 Dec 2025 | 3G · unquoted | ORDINARY FULLY PAID | 418.2M | Appendix 3G |
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 41.8M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| SPLAK | Performance rights | Condition-triggered | — | — | 41.8M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 11 Aug 2026 | Cheryl Maley | Buy entitlement/SPP | 17k | — | 13.5M | $10k | 3Y notice |
| 11 Aug 2026 | Dr Jeff Davies | Buy entitlement/SPP | 117k | — | — | $67k | 3Y notice |
| 11 Aug 2026 | Dr Russell Basser | Buy entitlement/SPP | 36k | — | — | $21k | 3Y notice |
| 11 Aug 2026 | Ms Lynda Cheng | Buy entitlement/SPP | 23k | — | — | $13k | 3Y notice |
| 11 Aug 2026 | Robert B. Thomas | Other entitlement/SPP | 350k | — | — | $200k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.